Unlocking healthcare potential for patients

Leveraging our expertise to address unmet medical needs

our products

Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals.

Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies.

Phase 2B*


Osteogenesis Imperfecta (OI) *POTENTIALLY PIVOTAL
Phase 2B


Hypogonadotropic Hypogonadism (HH)
Phase 2


Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)

partner with us

Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines.

Interested in a potential collaboration?


Share Price

View Share Price Chart

Events and conferences

  • 19 May 2017 Mereo BioPharma presented at at the American Thoracic Society meeting in Washington, 19-24 May 2017
  • 24 Jan 2017 Mereo BioPharma presented at at the Shares Spotlight Evening in London
  • 10 Jan 2017 Mereo BioPharma Group plc presented at the 9th Annual Biotech Showcase, 11:00am PST (San Francisco, USA)
View All Events